NEW YORK (GenomeWeb News) – MetaStat today said it has reached two exclusive licensing agreements for the use of alternatively spliced mRNA and protein isoform biomarkers.

The agreements are with the Massachusetts Institute of Technology and its David H. Koch Institute for Integrative Cancer Research at MIT and its department of biology, the Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The technology being licensed is for the diagnosis, prognosis, and treatment of metastasis in epithelial solid tumor cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.